Preparation and characterization of puerarin–dendrimer complexes as an ocular drug delivery system

References

• Xuan B, Zhou YH, Yang RL, Li N, Min ZD, Chiou GC. (1999). Improvement of ocular blood flow and retinal functions with puerarin analogs. J Ocul Pharmacol Ther, 15(3):207–16.
   PubMed Web of Science ®Google Scholar
• Yue PF, Yuan HL, Li XY, Yang M, Zhu WF, Xiao XH. (2007). Development and optimization of intravenous puerarin emulsions formation by a novel complex-phase inversion-homogenization technology. Chem Pharm Bull (Tokyo), 55(11):1563–8.
   PubMed Web of Science ®Google Scholar
• Wu CJ, Qi HY, Chen WW, Huang CY, Su C, Li WM, . (2007). Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi, 127(1):183–91.
   PubMed Web of Science ®Google Scholar
• Jain NK, Gupta U. (2008). Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug Metab Toxicol, 4(8):1035–52.
   PubMed Web of Science ®Google Scholar
• Stella VJ, Nti-Addae KW. (2007). Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev, 59(7):677–94.
   PubMed Web of Science ®Google Scholar
• Urtti A. (2006). Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev, 58(11):1131–5.
   PubMed Web of Science ®Google Scholar
• Tomalia DA, Baker H, Dewald JR, Hall M, Kallos G, Matrin S, . (1985). A new class of polymers: Starburst dendritic molecules. Polym J, 17(1):117–32.
   Web of Science ®Google Scholar
• Liu M, Frechet JM. (1999). Designing dendrimers for drug delivery. Pharm Sci Technolo Today, 2(10):393–401.
   PubMedGoogle Scholar
• Hawker CJ, Frechet JMJ. (1990). Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc, 112(21):7638–47.
   Web of Science ®Google Scholar
• D'Emanuele A, Attwood D. (2005). Dendrimer-drug interactions. Adv Drug Deliv Rev, 57(15):2147–62.
   PubMed Web of Science ®Google Scholar
• Gillies ER, Frechet JM. (2005). Dendrimers and dendritic polymers in drug delivery. Drug Discov Today, 10(1):35–43.
   PubMed Web of Science ®Google Scholar
• Cheng YY, Xu TW. (2005). Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem, 40(11):1188–92.
   PubMed Web of Science ®Google Scholar
• Yang H, Morris JJ, Lopina ST. (2004). Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J Colloid Interface Sci, 273(1):148–54.
   PubMed Web of Science ®Google Scholar
• Gupta U, Aqashe HB, Asthana A, Jain NK. (2006). Dendrimers: Novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules, 7(3):649–58.
   PubMed Web of Science ®Google Scholar
• Man N, Cheng YY, Xu TW, Ding Y, Wang XM, Li ZW, . (2006). Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem, 41(5):670–4.
   PubMed Web of Science ®Google Scholar
• Hong S, Bielinska AU, Mecke A, Keszler B, Beals JL, Shi X, . (2004). Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: Hole formation and the relation to transport. Bioconjug Chem, 15(4):774–82.
   PubMed Web of Science ®Google Scholar
• Venuganti VV, Perumal OP. (2009). Poly(amidoamine) dendrimers as skin penetration enhancers: Influence of charge, generation, and concentration. J Pharm Sci, 98(7):2345–56.
   PubMed Web of Science ®Google Scholar
• Venuganti VV, Perumal OP. (2008). Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil. Int J Pharm, 361(1–2):230–8.
   PubMed Web of Science ®Google Scholar
• Burnette RR, Ongpipattanakul B. (1987). Characterization of the permselective properties of excised human skin during iontophoresis. J Pharm Sci, 76(10):765–73.
   PubMed Web of Science ®Google Scholar
• Vandamme TF, Brobeck L. (2005). Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release, 102(1):23–38.
   PubMed Web of Science ®Google Scholar
• Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. (2003). Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm, 259(1–2):143–60.
   PubMed Web of Science ®Google Scholar
• Neerman MF. (2007). The efficiency of a PAMAM dendrimer toward the encapsulation of the antileukemic drug 6-mercaptopurine. Anticancer Drugs, 18(7):839–42.
   PubMed Web of Science ®Google Scholar
• Ma M, Cheng YY, Xu ZH, Xu P, Qu HO, Fang YJ, . (2007). Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem, 42(1):93–8.
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Aminabhavi TM. (2007). Chitosan nanoparticles for prolonged delivery of timolol maleate. Drug Dev Ind Pharm, 33(11):1254–62.
   PubMed Web of Science ®Google Scholar
• Yan Z, Xu W, Sun J, Liu X, Zhao Y, Sun Y, . (2008). Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-beta- cyclodexin. Drug Dev Ind Pharm, 34(6):632–41.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang DJ, Chen SL, Chen SB, Chan AS. (2007). Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods. Pharm Res, 25(3):563–77.
   PubMed Web of Science ®Google Scholar
• Klajnert B, Janiszewska J, Urbanczyk-Lipkowska Z, Bryszewska M, Epand RM. (2006). DSC studies on interactions between low molecular mass peptide dendrimers and model lipid membranes. Int J Pharm, 327(1–2):145–52.
   PubMed Web of Science ®Google Scholar
• Devarakonda B, Otto DP, Judefeind A, Hill RA, de Villiers MM. (2007). Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm, 345(1–2):142–53.
   PubMed Web of Science ®Google Scholar
• Cheng YY, Wu QL, Li YW, Xu TW. (2008). External electrostatic interaction versus internal encapsulation between cationic dendrimers and negatively charged drugs: Which contributes more to solubility enhancement of the drugs?. J Phys Chem B, 112(30):8884–90.
   PubMed Web of Science ®Google Scholar
• Boas U, Sontjens SHM, Jensen KJ, Christensen JB, Meijer EW. (2002). New dendrimer-peptide host-guest complexes: Towards dendrimers as peptide carriers. Chem Bio Chem, 3(5):433–9.
   Web of Science ®Google Scholar
• Bai S, Thomas C, Ahsan F. (2007). Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci, 96(8):2090–106.
   PubMed Web of Science ®Google Scholar
• Mansour M, Mansour S, Mortada ND, Abd ElHady SS. (2008). Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels. Drug Dev Ind Pharm, 34(7):744–52.
   PubMed Web of Science ®Google Scholar
• Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Rao YM. (2008). Polymers for mucoadhesive drug delivery system: A current status. Drug Dev Ind Pharm, 34(11):1246–66.
   PubMed Web of Science ®Google Scholar
• Maurice DM, Riley MV. (1970). Ocular pharmacokinetics. In: Gragmore CN, ed. Biochemistry of the eye. London: Academic Press, 6–16.
   Google Scholar
• Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. (2003). In vitro cytotoxicity testing of polycations: Influence of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials, 24(7):1121–31.
   PubMed Web of Science ®Google Scholar
• Singh I, Rehni AK, Kalra R, Joshi G, Kumar M. (2008). Dendrimers and their pharmaceutical applications-a review. Pharmazie, 63(7):491–6.
   PubMed Web of Science ®Google Scholar